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Abstract
Background: Cortisol is a hormone involved in many physiological functions including fetal maturation and
epigenetic programming during pregnancy. This study aimed to use hair cortisol as a biomarker of chronic inhaled
corticosteroid (ICS) exposure and assess the potential effects of asthma on the hypothalamic-pituitary-adrenal (HPA)
axis in pregnant women. We hypothesized that pregnant women with asthma treated with ICS would exhibit lower
hair cortisol concentrations, indicative of adrenal suppression, compared to women with asthma not using ICS and
women who do not have asthma.
Methods: We performed an observational retrospective cohort study. Hair samples were analyzed from pregnant
women with asthma, with (n = 56) and without (n = 31) ICS treatment, and pregnant women without asthma
(n = 31). Hair samples were segmented based on the growth rate of 1 cm/month and analyzed by enzyme
immunoassay to provide cortisol concentrations corresponding to preconception, trimesters 1–3, and postpartum.
Hair cortisol concentrations were compared within and among the groups using non-parametric statistical tests.
Results: Hair cortisol concentrations increased across trimesters for all three groups, but this increase was
dampened in women with asthma (P = 0.03 for Controls vs. ICS Treated and Controls vs. No ICS). ICS Treated
women taking more than five doses per week had hair cortisol concentrations 47 % lower in third trimester than
Controls. Linear regression of the third trimester hair cortisol results identified asthma as a significant factor when
comparing consistent ICS use or asthma as the predictor (F(1, 25) = 9.7, P = 0.005, R
2
adj = 0.257).
Conclusions: Hair cortisol successfully showed the expected change in cortisol over the course of pregnancy and
may be a useful biomarker of HPA axis function in pregnant women with asthma. The potential impact of
decreased maternal cortisol in women with asthma on perinatal outcomes remains to be determined.
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Background
Cortisol has many important functions in the body in-
cluding metabolism, regulation of blood pressure, and
roles in the inflammatory and stress responses. When
required, the hypothalamus and pituitary gland are acti-
vated to release a series of hormones that signal the ad-
renal cortex to release cortisol. Asthma is a common
chronic inflammatory disease for which the recom-
mended therapy for long-term control is inhaled cortico-
steroids (ICS) [1]. ICS bind to glucocorticoid receptors
in lung epithelial cells and reduce airway inflammation.
Binding also mimics endogenous cortisol and conse-
quently initiates a negative feedback resulting in de-
creased cortisol release from the adrenal glands. While
generally believed to confer less systemic exposure than
systemic corticosteroids, in severe cases, the use of ICS
may cause adrenal insufficiency or crisis [2, 3].
Classically, the matrices used to measure a patient’s
cortisol level are blood, saliva, or urine. However, these
matrices do not account for the diurnal nature of corti-
sol secretion and only reflect the point in time when
sampling is conducted [4]. More recently, hair analysis
has emerged as a viable alternative for cortisol detection.
Hair cortisol levels correlate with a 24-h urine sample
(r = 0.33, p = 0.04) and multiple saliva samples col-
lected over 7 days (r = 0.41, p = 0.03) [4, 5]. Since hair
grows on average one centimeter per month (cm/mo)
([6], p. 2), the cortisol detected in a one-centimeter
hair segment represents the average cortisol level over
the corresponding one-month period.
Hair cortisol has previously been used to assess the ef-
fects of various medical conditions on the hypothalamic-
pituitary-adrenal (HPA) axis, including psychological
and physical stressors. It is already known that cortisol
concentrations increase in relation to a stressful event,
and these changes were reflected in the hair of children
fearful of beginning school and individuals who recently
experienced a traumatic event [7–9]. Similarly, hair cor-
tisol concentrations in patients diagnosed with Cushing
syndrome corresponded to the characteristic increased
endogenous cortisol concentrations, with 86 % sensitivity
and 98 % specificity for the detection of cyclic Cushing’s
syndrome [10, 11]. Recently, we examined hair cortisol of
children with asthma due to concerns of potential adverse
effects from long-term ICS therapy [12]. Our results
showed a 55 % decrease in hair cortisol concentration dur-
ing ICS therapy compared to prior to ICS therapy suggest-
ing significant ICS-induced HPA axis suppression and
providing further support for using hair as a matrix for
measuring cortisol.
In 2001 in the United States, the prevalence of asthma
in pregnancy was 8 % [13]. Only one study has examined
hormone concentrations, including cortisol, among
pregnant women with asthma with and without ICS
treatment as compared to pregnant women without
asthma and found no difference among the three groups
[14]. Given that cortisol is a vital factor in fetal lung,
gastrointestinal tract, kidney, and thyroid maturation
[15], our objective was to use hair cortisol as a bio-
marker to investigate cortisol changes over the course of
pregnancy in the context of potential adverse effects of
ICS on the HPA axis in pregnant women with asthma.
We hypothesized that pregnant women with asthma
treated with ICS would exhibit lower hair cortisol con-
centrations, suggestive of adrenal suppression, compared
to women with asthma not using ICS and women who
do not have asthma.
Methods
Study design, participants, and ethics
We performed a retrospective observational cohort study.
Three groups of pregnant women were recruited from
June 2012 to December 2014: women with ICS-treated
asthma (ICS Treated), and two comparison groups con-
sisting of women without asthma (Controls) and a
disease-matched group of women with asthma not treated
with ICS (No ICS). The sample size was not formally de-
termined due to the unavailability of data on hair cortisol
concentrations in pregnant women with and without
asthma when the protocol was created. Participants were
recruited in person in obstetric clinics at the British
Columbia Women’s Hospital and Health Centre in
Vancouver, British Columbia, and St. Michael’s Hospital in
Toronto, Ontario. Additionally, women were recruited
through the Hospital for Sick Children’s Motherisk
Program teratology information service via telephone and
mail. All pregnant women were eligible provided they
could read and understand English, did not use any cor-
ticosteroid products on their scalp, or have any known
medical conditions characterized by high cortisol levels
such as Cushing’s syndrome. Women were recruited at
any time during pregnancy up to 6 months postpartum.
Research ethics board approval was obtained from each
institution and informed written consent was obtained
from all participants.
Data collection
Relevant clinical information was obtained through med-
ical record review and/or patient interview and included
asthma and ICS treatment history and concomitant
medications. Factors reported to affect hair cortisol
levels, such as frequency of hair washing, days since last
washing and chemical treatment (color or relaxer), were
also collected [16]. Additionally, the Perceived Stress
Scale (PSS), a validated tool to assess stress levels experi-
enced in the previous month, was administered to
women enrolled in Ontario [17].
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Hair sample collection and analysis
A lock of hair approximately 3 mm thick (equivalent to
one-half the diameter of a pencil) was cut from the ver-
tex posterior region of the head as close to the scalp as
possible. Based on an average growth rate of 1 cm/mo,
each hair sample was further cut into segments 2–
3.6 cm in length (the majority were 3 cm long) to cor-
respond to preconception (PC), trimesters 1–3 (T1, T2,
T3), and immediate postpartum (PP) time points as
available depending on the hair length and collection
date ([6], p. 2). Day 0 of each hair sample was considered
fourteen days prior to date of hair collection to account
for the fact that 10–14 days of hair resides below the
scalp ([6], p. 35). Segmented hair samples were proc-
essed for hair cortisol extraction as previously reported
[18], with a few minor modifications. In brief, each sam-
ple of 10–25 mg of hair was washed twice with isopro-
panol and allowed to dry, and then finely minced with
scissors and extracted overnight in methanol. After re-
moving all of the supernatant, samples were dried under
N2 at 37 °C, reconstituted with 125 μL of phosphate
buffered saline, and vortexed for one minute. Initially,
samples were reconstituted with 250 μL, but this re-
sulted in some samples having results below the quanti-
tation limit (0.33 pmol/mL or 0.12 ng/mL).
The samples were analyzed using the Salimetrics High
Sensitivity Salivary Cortisol Enzyme Immunoassay (EIA)
kit (Salimetrics, Philadelphia, PA) following the manu-
facturer’s instructions. All of the % cross-reactivity re-
ported by the manufacturer is less than 0.6 % for other
steroid hormones, such as prednisolone, prednisone, or
cortisone, except for dexamethasone, which was 19.2 %.
Additionally, the cross-reactivity was determined for
each of the ICS available in Canada using an 8000 ng/
mL solution run six times on two different EIA plates.
The results were not detectable for fluticasone propionate,
budesonide and ciclesonide, 0.01 % for beclomethasone
dipropionate, and 0.03 % for mometasone furoate. Hair
cortisol concentrations measured using this kit have been
correlated to two different liquid chromatography-mass
spectrometry methods with a Spearman rho of ≥ 0.92
(P < 0.0001) [19].
In addition to the quality control material included
with the kit, a pooled in-house hair sample was run as a
third quality control and the results were evaluated
using Westgard Rules for acceptance or rejection. The
results of the EIA were considered acceptable if two of
three control values were within expected range. Based
on the coefficients of variation for the participant sam-
ples, the average intra-day coefficient of variation was
6.3 %. The average inter-day coefficients of variation
were 1.5 and 4.5 % for the high and low quality control,
respectively. Because all samples are run in duplicate
with EIA analysis, any duplicates that had a coefficient
of variation greater than 15 or 20 % for results greater
than or lower than approximately 3 pmol/mL (1 ng/mL),
respectively, were reanalyzed or reprocessed based on
sample availability. Cortisol concentrations are reported
as a ratio to the hair sample weight (pmol/g).
Statistical analysis
Statistical analysis was performed using Graphpad Prism
software, version 5.0c (Graphpad Software, Inc., La Jolla,
CA) and SPSS, version 22.0 (IBM Corporation, New York,
NY). Comparisons between the groups for hair cortisol
concentrations, demographic information, and clinical in-
formation were performed using one-way analysis of vari-
ance with Tukey’s multiple comparison test, the Kruskal-
Wallis test with Dunn’s multiple comparison test, and
Chi-square test or Freeman-Halton extension of the
Fisher’s exact probability test as appropriate for normally
or not normally distributed, and categorical data. Further
post hoc analyses were performed using the unpaired t-test
with Welch’s correction, and Mann–Whitney U test with
Bonferroni correction for multiple comparisons to calcu-
late the adjusted p-values (Padj), as needed.
The Friedman test was used to compare hair cortisol
concentrations for the five time points within each
group. Because most women did not have results for all
five time points, post hoc analysis for the Friedman test
was performed using the Wilcoxon matched-pairs signed
rank test. A natural log transformation was required for
the hair cortisol data prior to performing the Wilcoxon
tests to best satisfy statistical assumptions. The Holm-
Bonferroni correction was applied to p-values to correct
for multiple comparisons. Additionally, the linear regres-
sion for median hair cortisol concentrations from PC to
T3 for each group were compared using analysis of co-
variance with the Bonferroni correction for multiple
comparisons to calculate the adjusted p-values. Univari-
ate and multiple linear regressions were performed with
the variables “consistent ICS use” (defined as use of ICS
for ≥ 5 doses per week), “intranasal corticosteroid use”
(yes/no), and “asthma” (yes/no) for T3 to determine if
there was any influence of these variables on hair
cortisol concentrations in that trimester.
Spearman correlations were calculated for the hair
cortisol results with previously published confounders,
including the age of hair sample, body mass index (BMI)
(pre-pregnancy and at time of hair collection), number
of hair washes per week, days since last washing, and
PSS score. Because hair chemical treatment is a binary
outcome, a point biserial correlation was performed
using natural log transformed hair cortisol concentra-
tions with concentrations ≥ 276 pmol/g removed to best
satisfy the assumption of normally distributed data,
which was unsuccessful for the PC concentrations in the
treated asthma group. Correlations with the hair
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segment length were added post hoc when the segment
lengths were finalized and some deviated from 3 cm.
In all cases, two-tailed p-values were calculated and
considered significant if ≤ 0.05.
Results
Participant results and demographic comparison
Hair samples were analyzed for 118 pregnant women,
consisting of 31 Controls, 31 No ICS, and 56 ICS
Treated. Fourteen additional hair samples from the ICS
Treated group could not be analyzed due to insufficient
quantity, inaccurate segmentation, ICS being used to
treat a condition other than asthma, or hair being col-
lected too early in T1 (i.e., if the hair segment was less
than 2 cm) or >6 months postpartum. Some of the first
hair samples analyzed had cortisol concentrations below
the quantitation limit (0.33 pmol/mL) but could not be
repeated due to insufficient quantity of the original hair
sample; therefore, these results were recalculated using
the quantitation limit. This recalculation predominantly
affected the No ICS group (n = 5 patients/12 segments)
compared to the Controls (n = 3 patients/3 segments) or
ICS Treated (n = 2 patients/3 segments).
Comparisons of demographics, hair variables, and
medication use among the groups are listed in Table 1.
Overall, there were no significant differences among the
three groups except for their use of intra-nasal cortico-
steroids and beta-agonists, which, as anticipated, were
more frequent among women with asthma (Table 1). As-
sociations between the hair cortisol results and factors
previously reported to affect hair cortisol concentrations
were further explored but no significant confounding ef-
fects were found (see Additional file 1: Table S1). There-
fore, the test statistics were not adjusted for any of these
factors. Of the women recruited postpartum or in T3,
only one woman in the No ICS group received
Table 1 Comparison of demographics, hair variables, and medication use among the three groups of pregnant women
Controls
(n = 31)
No ICS
(n = 31)
ICS treated
(n = 56)
P
Demographics
Age, years, mean (SD) 33.8 (4.3) 31.6 (6.0) 33.3 (5.5) 0.240k
BMI, kg/m2, median (IQR, n)
Pregnant 28.8 (25.4–32.5, 31) 28.2 (25.0–34.2, 25) 27.8 (24.7–32.2, 41) 0.716l
Pre-Pregnancy 24.6 (20.9–27.2, 31) 25.8 (22.8–31.3, 25) 24.8 (21.8–29.4, 42) 0.554l
PSS Score, mean (SD, n) 12 (5–26) 15 (7–9) 15 (6–23) 0.210k
Birth Dataa
Gestational age, weeks, median (IQR, n) 39.6 (39.0–40.9, 30) 39.1 (37.6–40.6, 28) 39.1 (38.1–40.3, 51) 0.155l
Birth weight, kg, median (IQR, n) 3.41 (3.11–3.65, 31) 3.37 (2.76–3.64, 30) 3.31 (2.89–3.63, 52) 0.701l
Hair Sample Variables
Sample age, daysb, mean (SD) 334 (82) 325 (93) 315 (103) 0.661k
# Washes per week, median (IQR, n) 3.5 (2.5–4.5, 31) 3.0 (2.5–5.5, 24) 4.0 (3–6.6, 42) 0.141l
# Days since last washed, median (IQR, n) 1 (0–2, 29) 1 (0–1, 23) 1 (0–1, 37) 0.375l
Chemical treatmentc, n (%) 19 (61.3) 17 (of 26, 65.4) 25 (of 47, 53.2) 0.563m
Medication Use During Pregnancy
Inhaled corticosteroid used, Yes/No No No Yes –
Oral corticosteroid usee, n (%) 0 (0) 3 (9.7) 4 (7.1) 0.280m
Intranasal corticosteroid usef, n (%) 3 (9.7)h 2 (6.5)h 16 (28.6) 0.014m
Topical corticosteroid usef, n (%) 5 (16.1) 2 (6.4) 7 (12.5) 0.343m
Other steroid hormone use (e.g., progesterone)f, n (%) 3 (9.7) 4 (12.9) 6 (10.7) 0.867m
Beta-agonistf,g, n (%) 2 (6.4)i 24 (77.4)j 54 (96.4) <0.0001m
Number of other classes of medications usedf, median (IQR) 2 (1–3) 2 (0–4) 2 (1–3) 0.650l
BMI body mass index, PSS perceived stress scale, IQR interquartile range, SD standard deviation
aInclusive of data for twin births, the frequency of which was not significantly different among the groups. bThe age is calculated to the oldest part of the hair
sample at the beginning of the preconception segment. cFor No ICS and ICS Treated, information regarding chemical treatment (color or relaxer) was not
available for all women. The total number of women is indicated in the parentheses. dInhaled corticosteroid use includes any use within the time captured by the
tested hair segment, regardless of frequency or duration. eOral corticosteroid use is reported if within one month prior to the tested hair segment. fUse within the
last 12 months, which may not be during pregnancy. gIncludes beta-agonist drugs that are short and long-acting, including use of combination inhaler products.
hSignificantly different from ICS Treated, P < 0.05. iSignificantly different from both No ICS and ICS Treated, P < 0.0001. jSignificantly different from ICS Treated
P < 0.01. kOne-way analysis of variance with Tukey’s multiple comparison test. lKruskal-Wallis test with Dunn’s multiple comparison test. mChi-squared or Freeman-
Halton extension of the Fisher’s exact probability test, as appropriate. Significant P-values are in bold
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corticosteroids due to threatened preterm labour during
the time point captured by her hair sample. It is un-
known whether any of the women received hydrocorti-
sone stress dose treatment during labour.
Hair cortisol concentrations increase during pregnancy
Hair cortisol concentrations for each time point are
shown in Fig. 1. A similar increase in cortisol over the
course of pregnancy from PC to T3, followed by a de-
cline PP, was evident for all three groups, although this
trend was less pronounced for the two groups of women
with asthma. There were seven patients (five ICS
Treated and two No ICS) with a decline in hair cortisol
concentrations from PC to T2. Additionally, there was a
subgroup of three women with 11 samples with hair cor-
tisol concentrations ≥ 276 pmol/g consisting of one Con-
trol for segments PC to PP, and two ICS Treated for
segments PC to T3 and T3 to PP (Fig. 1). The cortisol
concentrations for the Controls differed significantly
across all time points (χ2(4) = 9.6, P = 0.028, n = 4) and in-
creased from 7.9 pmol/g (IQR 3.8–17.0 pmol/g, n = 29)
in PC to 21.1 pmol/g (IQR 14.7–31.0 pmol/g, n = 11) in
T3. The ICS Treated group also showed overall signifi-
cant changes in cortisol (χ2(4) = 21.4, P < 0.001, n = 7) as
well as an increase between PC (7.9 pmol/g, IQR 5.4–
14.2 pmol/g, n = 50) and T3 (14.2 pmol/g, IQR 10.2–21.7
pmol/g, n = 19). Only the No ICS group did not have a
significant overall change in cortisol across all time points
(χ2(4) = 2.1, P = 0.768, n = 3) but did show a similar trend of
increasing cortisol from PC (8.2 pmol/g, IQR 4.8–12.4
pmol/g, n = 29) to T3 (13.0 pmol/g, IQR 8.8–15.7 pmol/g,
n = 9), although the increase from PC to T3 was also not
significant (χ2(4) = 2.0, P = 0.583, n = 8). Generally, post hoc
analyses revealed significant differences over the course of
pregnancy between hair cortisol concentrations during PC
and T1 compared to T2 and onward for the Controls and
ICS Treated (Fig. 1).
Hair cortisol increase during pregnancy is dampened in
women with asthma
When the median hair concentrations from PC to T3 were
plotted for each group to determine the slopes of the re-
gression lines for the change in cortisol during pregnancy,
there was a significant difference among the three slopes
(F(2,6) = 14.8, P = 0.005) (Fig. 2a). Comparing the slopes to
one another, the change in median hair cortisol concentra-
tions from PC to T3 for the Controls was significantly dif-
ferent from the ICS Treated (F(1,4) = 22.6, Padj = 0.026) and
a b c
Fig. 1 Scatter plots of median hair cortisol concentrations. Median hair cortisol concentrations (horizontal bar) in pmol/g of hair are shown for
each group of pregnant women (a - Controls, b – No ICS, c – ICS Treated) by pregnancy time point consisting of preconception (PC), first
trimester (T1), second trimester (T2), third trimester (T3), and postpartum (PP). Hair cortisol is plotted on a log10 y-axis. Sample sizes for each time
point are shown below the x-axis. The change in cortisol over the five time points was significant for the Controls and ICS Treated. Post hoc analysis
showed significant differences between time points as indicated in the figure. When analyses were repeated with all hair cortisol concentrations≥ 276
pmol/g removed, the results were not greatly changed. The alternate p-values are shown in parentheses, ( ). Holm-Bonferroni correction for multiple
comparisons was applied to all p-values. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001
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No ICS (F(1,4) = 20.2, Padj = 0.033), whereas there was no
significant difference between the No ICS and ICS
Treated (F(1,4) = 0.1, Padj = 2.29). When the subgroup of
women with samples with concentrations ≥ 276 pmol/g
were excluded as potential confounders, the comparison
between the Controls and No ICS was no longer signifi-
cant (F(1,4) = 13.5, Padj = 0.064) (Fig. 2b).
Hair cortisol concentrations are lower in third trimester
for women with asthma
All groups had a similar median hair cortisol concentra-
tion at PC and T1 with differences becoming apparent
in T2 and T3 (Fig. 3a, b). When cortisol levels for each
individual time point were compared among the groups,
although there was a visible difference between the Con-
trols and two asthma groups for T3, the results were not
significant (χ2(2) = 5.1, P = 0.078) (Fig. 3a) and performing
the statistical analyses with and without the concentra-
tions ≥ 276 pmol/g yielded similar results. However, if
the cortisol results for all women with asthma were
combined, the mean T3 cortisol concentration was sig-
nificantly lower compared to the Controls (t(34) = 2.189,
P = 0.036). Furthermore, when women who reported ICS
use less than five doses per week and concentrations
≥ 276 pmol/g were excluded as potential confounders,
the T3 median hair cortisol concentration for the ICS
Treated group was significantly lower (47 %) than the
Controls (19.9 pmol/g vs. 10.6 pmol/g, U = 9, Padj =
0.029) (Fig. 3b). Univariate and multiple linear regression
analysis to determine the influence of consistent ICS
use, intranasal corticosteroids, or asthma on the T3 hair
cortisol concentration showed that asthma was the only
significant factor (F(1, 25) = 9.7, P = 0.005, R
2
adj = 0.257).
When the samples with concentrations ≥ 276 pmol/g
were included (with ICS use still restricted to five or
more doses per week), the median hair cortisol concen-
trations at T3 for ICS Treated group was still 48 % lower
than the Controls, but the difference was no longer sig-
nificant (21.1 pmol/g vs. 11.0 pmol/g, U = 29, Padj =
0.386) (Fig. 3c).
Discussion
This study is the first to investigate the use of hair cortisol
as a biomarker to assess asthma and the potential effects
of ICS on the HPA axis in pregnant women. The 2- to 3-
fold increase in serum or salivary cortisol over the course
of normal pregnancy compared to a non-pregnant state is
well-documented [20–22]. Our findings, which showed an
increase in hair cortisol concentrations over the course of
pregnancy for all groups, are in line with previous hair
cortisol research [23–25], and, specifically, the 2- to 3-fold
increase in hair cortisol concentrations for the Controls
corresponds well with the previous serum and saliva
research. Moreover, we also found a suppressed adrenal
response over the course of pregnancy in women with
asthma compared to women without asthma, most not-
ably in T3.
Our results are in contrast to findings reported previ-
ously that did not find a significant difference in serum
cortisol concentrations among pregnant women with
asthma, with and without ICS treatment, and pregnant
women without asthma [14]. Limitations of the previous
b
Fig. 2 Comparison of the change in hair cortisol concentrations
during pregnancy. The linear regressions for median hair cortisol
concentrations for each group of pregnant women from PC to T3
are shown. The similarity of the slopes for the No ICS and ICS
Treated groups can be seen. The difference of those slopes from the
slope for the Controls is significant if the samples with
concentrations ≥ 276 pmol/g are included (a), but when they are
excluded (b), the comparison between the Controls and No ICS is
no longer significant. PC = preconception, T1 = first trimester,
T2 = second trimester, T3 = third trimester
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study was that serum cortisol was only assessed on one
occasion per trimester for each participant in a 3-h time
window, and the sample collection timing varied over a
4 to 9-week period of each trimester. Moreover, the
sample collection for T3 occurred during 25–34 weeks
of gestation, which is considered late T2 or early T3.
This sampling pattern may not have fully captured the
dynamic changes in cortisol that occur during preg-
nancy, including the rise in cortisol during T3 as seen in
our study. Thus, our results suggest that using hair as
the sample matrix, which is representative of the average
cortisol levels for the entire trimester, may be more sen-
sitive for detecting changes in cortisol between each tri-
mester and is a significant advantage of our study.
Based on previous reports of the association between
decreased cortisol production and ICS therapy [3, 12], it
was anticipated that pregnant women using ICS might
have decreased cortisol concentrations compared to
both comparison groups. A significant decrease was ap-
parent for women who used more than five ICS doses
per week throughout pregnancy, but only in T3 when
compared to Controls and if the three women with hair
cortisol concentrations ≥ 276 pmol/g were excluded.
Unexpectedly, the No ICS group showed a diminished
adrenal response over the course of pregnancy from PC
to T3 similar to the ICS Treated group. One possible ex-
planation for the lower hair cortisol concentrations in
women with asthma may be sustained overwork and
resultant fatigue of the HPA axis [26]. Research shows
that the initial response to stress is increased cortisol
production with decreased expression of pro-inflammatory
cytokines; however, with chronic exposure to stress hor-
mones there is a decrease in immune system sensitivity
and response to cortisol, ultimately resulting in increased
pro-inflammatory cytokines [26]. Pregnancy generates an
inflammatory state and approximately one-third of
women experience increased asthma symptoms when
pregnant [27]. It is possible that the added physiological
stress due to pregnancy in combination with asthma, or
the woman’s asthma severity or chronic state, exacerbates
HPA axis fatigue through chronic exposure to stress hor-
mones and ultimately leads to a decreased cortisol re-
sponse regardless of ICS use. This is supported by the
linear regression analysis of our data for T3 that indicates,
between consistent ICS use, intranasal corticosteroid use,
and asthma, asthma accounted for approximately 26 % of
the decrease observed. Also, in support of our findings,
patients with chronic asthma were previously found to
have a decreased response to adrenocorticotropic hor-
mone stimulation, but research is limited in this area [28].
Alternatively, the less-pronounced increase in hair cortisol
during pregnancy in women with asthma may be due to
decreased cortisol sensitivity from a reduction in gluco-
corticoid receptors [26], as found in children with asthma
who were shown to have a 5.5-fold decrease in expression
of the glucocorticoid receptor [29]. Further research com-
paring hair cortisol concentrations in healthy adults to
those with asthma, with and without ICS treatment, may
confirm whether the observed difference in cortisol con-
centrations is due to HPA axis fatigue from the physio-
logical stress of pregnancy rather than asthma chronicity
or severity.
The prevalence of adrenal insufficiency or suppression
in pregnancy is currently not well documented. This is
in part due to the dynamic and significant increases of
cortisol during pregnancy potentially masking any deficit
a b c
Fig. 3 Bar graphs comparing median hair cortisol concentrations. The median hair cortisol concentrations (y-axis) at each time point (x-axis) for
Controls, No ICS, and ICS Treated are shown. Sample sizes for each time point are shown below the x-axis. a. Comparison inclusive of all women
in the ICS Treated group who reported ICS use captured in the hair sample, regardless of frequency or duration, showing no significant difference
among the three groups. b Comparison excluding women with hair cortisol concentrations ≥ 276 pmol/g and women in the ICS Treated group
who reported ICS use less than five doses per week showing a significant difference between Controls and ICS Treated women in T3. However,
when the samples with concentrations ≥ 276 pmol/g were included, the comparison was no longer significant (c). *P ≤ 0.05, error bars indicate
the interquartile range, PC = preconception, T1 = first trimester, T2 = second trimester, T3 = third trimester, PP = postpartum
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[21], and a lack of reference intervals specific to preg-
nancy. Previous research has largely focused on the fetal
and perinatal outcomes of fetal exposure to increased ma-
ternal cortisol concentrations [30, 31], leaving a large gap
in knowledge on the potential adverse effects of decreased
cortisol levels. Our study suggests that women with
asthma during pregnancy experience adrenal suppression,
which may represent adrenal hypo-functionality that is
less severe than that of adrenal insufficiency but could po-
tentially still impact pregnancy outcomes and normal fetal
maturation. Research shows that women with asthma,
with or without ICS treatment, have similar perinatal out-
comes to women with autoimmune adrenal insufficiency.
Both groups are more likely to require a Cesarean section
or have a preterm birth [32–34], potentially indicating a
link with decreased cortisol levels. Our data do not sug-
gest women with asthma experience preterm birth
(Table 1), but our sample size may be too small to detect a
significant difference. Yet, the results of a recent publica-
tion investigating the determinants of maternal hair corti-
sol at delivery support an association between preterm
birth and decreased cortisol. Although they did not take
asthma or other diseases into consideration, Braig et al.
[35] found that women who had premature babies
(≤ 37 weeks of gestation) had significantly lower hair corti-
sol levels in the three months prior to delivery (β = −0.16,
P = 0.029). However, this significance did not remain when
the regression model was adjusted for all other significant
variables considered by the researchers (mutually adjusted
β = −0.10, P = 0.157). Nevertheless, our research and that
of Braig et al. supports the premise that hair cortisol is a
useful tool for future research to ascertain whether there
is an association between decreased maternal cortisol and
pregnancy outcomes. We were unable to find any fur-
ther research reporting on pregnancy outcomes for
women with lower-than-normal cortisol production
suggesting that the condition has possibly gone un-
detected until now, thus indicating an advantage of hair
cortisol as a biomarker of adrenal function during
pregnancy.
The surges in cortisol from fetal and maternal sources
during pregnancy both likely contribute to fetal maturation.
Multiple mechanisms, such as the release of placental cor-
ticotropin releasing hormone and adrenocorticotropic hor-
mone, result in increased maternal cortisol as pregnancy
progresses, and the surge in cortisol in late pregnancy is
involved in epigenetic processes that program fetal
cardiovascular, neurologic, endocrine, and metabolic sys-
tems [21, 31]. If the required surge in cortisol is dimin-
ished, as was evident in our study in women with asthma,
organ systems that rely on cortisol for maturation and
programming may be adversely affected. Only one study
has examined the long-term effects of asthma and asthma
treated with ICS on childhood disease. The Danish
National Birth Cohort followed children to 6 years of age
and found that children exposed to ICS in utero were
more likely to experience ‘endocrine, metabolic disorders’
(hazard ratio (HR) = 1.84, CI95% 1.13–2.99) and digestive
system diseases (HR = 1.54, CI95% 1.18–2.02) [36]. Second-
ary analyses assessing the effects of maternal asthma, com-
bining those with and without ICS treatment, revealed an
increased risk of diseases of the respiratory system (HRadj =
1.43, CI95% 1.34–1.52), nervous system (HRadj = 1.43, CI95%
1.18–1.73), and digestive system (HRadj = 1.17, CI95% 1.04–
1.32) [37], all of which rely on cortisol for proper fetal mat-
uration or programming [15, 30, 31]. Although our present
study was not designed to draw conclusions on the effect of
decreased cortisol levels and disease risk in children born
to women with asthma, the growing evidence may warrant
further research in this area.
Limitations of our study include its relatively small
sample size and possible discrepancies in how the hair
was collected (e.g., scalp location, distance from scalp).
Given the observed expected change in hair cortisol
concentrations over the course of pregnancy, any in-
accuracy due to improperly collected samples is not ob-
vious, nor expected to be significant. Additionally, all
medication use was self-reported, either to the study
personnel or a healthcare provider. Generally, women
tend to reduce their ICS use during pregnancy [38, 39],
and some women in our study reported this, but issues
with recall may affect the reporting of ICS and other
medications. Finally, a positive bias could have occurred
for the recalculated cortisol concentrations that were
below the method quantitation limit. This predomin-
antly affected the No ICS group for PC, T1, and T2 and
may have reduced potential differences between this
group and the Controls. Although the degree of bias
cannot definitively be determined, future studies involv-
ing a larger number of women would be beneficial and re-
solve any uncertainty.
Conclusions
Our findings suggest that hair cortisol may be a useful
biomarker of HPA axis function during pregnancy and
sensitive enough to detect the effects of asthma, both with
and without ICS treatment, on systemic cortisol levels.
Using hair cortisol analysis, we are the first to show that
pregnant women with asthma are potentially unable to
mount the expected cortisol response seen in later preg-
nancy regardless of ICS use. Perinatal outcomes that are
known to be associated with maternal asthma may thus
be a result of decreased maternal cortisol that adversely
impacts fetal maturation and epigenetic programming.
Building upon our current work, future research on the
effects of maternal cortisol levels on pregnancy outcomes
could benefit from using hair cortisol analysis as an assess-
ment tool.
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